Following the lead of regulators in the UK, the US Food & Drug Administration has granted orphan drug status to IntraBio IB1000s, which the company believes may be able to “improve the quality of life of SCA patients by reducing their most debilitating symptoms.”

Additionally, Oxford-based Intrabio believes the new drug series may eventually have applications for the treatment of Niemann-Pick disease Type C, GM2 Gangliosidosis, and 17 other conditions (including ALS, Parkinsonisms, MS, Lewy Body Dementia, and Restless Leg Syndrome).